Gamida Cell Ltd.

Gamida Cell Ltd. is an advanced cell therapy company based in Israel that is committed to finding cures for patients with cancer and other serious diseases. The company was founded in 1998 by Dr. Tony Peled and Dr. Reuven Or, who developed a novel technology platform called NAM (Nicotinamide) that enhances the functionality and potency of cell therapies.

The company's headquarters are located in Jerusalem, and it has a manufacturing facility in Kiryat Gat. The company is publicly traded on the Nasdaq under the ticker symbol GMDA and has a market cap of about $116.3 million as of May 2023.

The company's vision is to create a pipeline of NAM-enabled cell therapies that can deliver a curative approach for patients with cancer and other diseases that are not adequately addressed by existing treatments. The company's lead product candidate is omidubicel-onlv, an allogeneic cell therapy for patients with hematologic malignancies who need a bone marrow transplant. Omidubicel-onlv received FDA approval in April 2023, making it the first NAM-enabled cell therapy to reach the market.

The company is also developing GDA-201, a natural killer (NK) cell therapy for patients with solid tumors and lymphomas. GDA-201 is currently in phase 1/2 clinical trials and has shown promising results in terms of safety and efficacy. The company has received several awards and recognitions for its innovative research and development, such as the Frost & Sullivan Technology Innovation Award, the Israel Innovation Authority Grant, and the BioWorld MedTech Breakthrough Award.

Foundation: 1998

Headquarters: Jerusalem, Israel

Website: https://www.gamida-cell.com/